GE HealthCare and Swiss Medical Network have signed an agreement to advance molecular imaging and theranostics research at the Department of Nuclear Medicine.
The collaboration aims to expand access to precision medicine, using both entities’ expertise and follows a strategic cooperation agreement signed in 2022.
It will establish a GE HealthCare Centre of Excellence in molecular imaging and theranostics at Clinique de Genolier, which is a part of the Swiss Medical Network.
The new centre will focus on enhancing precision diagnostics and treatment options.
GE HealthCare president and CEO Peter Arduini said: “We are excited to deepen our collaboration with Swiss Medical Network and its academic partners in Switzerland’s public sector.
“This agreement represents a step forward in our shared mission to advance molecular imaging and theranostics, ultimately delivering more connected and personalized care for better patient outcomes.
“The agility of the Swiss Medical Network enables us to rapidly validate and adopt innovative technologies, including AI-driven capabilities, and advance the future of healthcare.”
The advancement of precision diagnostics and regulatory approval of new treatments is bolstering the practice of precision medicine, particularly theranostics.
Theranostics combines diagnostic technologies with targeted therapies to diagnose, monitor, and treat cancers, and has seen significant successes in major cancers.
GE HealthCare is promoting theranostics through its imaging portfolio, including PET/CT and SPECT/CT, molecular imaging agents, isotopes, cyclotrons, and AI-driven solutions.
Swiss Medical Network chief science officer Med Jacques Bernier said: “As Swiss Medical Network remains committed to advancing the latest diagnostic and therapeutic technologies to enhance patient outcomes, GE HealthCare stands as a pivotal partner.
“With its deep expertise in molecular and diagnostic imaging, GE HealthCare plays a crucial role in fostering research synergies across the nationwide Swiss Medical Network, driving scientific and clinical excellence forward.”
To advance theranostics, GE HealthCare is providing equipment, unique tools, and technological support to facilitate research projects and meet clinical demands.
The Swiss Medical Network has upgraded its nuclear medicine platform, relocating to new facilities at Genolier Campus and Clinique Générale Beaulieu in the Lake Geneva Area.
It has adopted GE HealthCare’s imaging technologies, such as the Omni Legend 32 PET/CT system, StarGuide advanced SPECT/CT system, and 870DR general-purpose SPECT/CT.
Swiss Medical Network development director and nuclear Medicine medical director Antoine Leimgruber said: “The involvement of a global innovator like GE HealthCare is a testament to the growing complexity of cancer care and underscores the importance of investing in medical research.
“This commitment enables healthcare professionals to deliver the latest diagnostic and therapeutic options to patients.
“Constantly challenging ourselves to adopt and develop new technologies is critical in our pursuit of excellence, as is adapting our medical practices in the rapidly evolving medical field to the benefit of the patient.”
